RxDoctor Payments Data

Lanway Ling, MD

Family Medicine · Pensacola, FLNPI 1932173598

Payments from drug & device makers

$13,803in general payments, 2019–2025

Across 512 payments — averaging $26.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sage Therapeutics, LLC$5K
  • Novo Nordisk$1K
  • AbbVie$934
  • GSK$830
  • AstraZeneca$665
  • Pfizer$555
  • plus $4K from 41 others

What the payments were for

  • Food & beverage$8,48499%
  • Education$1001%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$13,803 in reported general payments places this provider in the 90th percentile of 7,282 family medicine providers in Florida.

See all family medicine providers in Florida

Medicare billing

Part B allowed, 2024
$283,800
Medicare patients
456
Services billed
3,974

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide94$111,801
EliquisApixaban63$63,818
OzempicSemaglutide55$55,766
JanuviaSitagliptin Phosphate49$42,205
XareltoRivaroxaban21$32,581
JardianceEmpagliflozin33$32,544
GlyxambiEmpagliflozin/Linagliptin17$18,375
FarxigaDapagliflozin Propanediol29$16,501
TrulicityDulaglutide14$11,620
VascepaIcosapent Ethyl12$8,302
Rosuvastatin Calcium334$6,032
MyrbetriqMirabegron14$6,010
SynthroidLevothyroxine Sodium61$5,764
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog18$5,700
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen182$4,763

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$391$123,421108 claims
PfizerEliquis, Paxlovid$555$65,24881 claims
Novo NordiskOzempic$1,214$55,76655 claims
Boehringer IngelheimJardiance, Glyxambi$353$50,92050 claims
MerckJanuvia$193$42,20549 claims
Johnson & JohnsonXarelto$147$32,58121 claims
AstraZenecaFarxiga$665$16,50129 claims
Astellas Pharma US IncMyrbetriq$160$6,01014 claims
AbbVieSynthroid$934$5,76461 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$18$3,752239 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 7,282 family medicine providers in Florida.

Other family medicine in Pensacola

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →